RMB, https://www.cambridgecognition.com/blog/entry/new-fda-draft-guidance-on-clinical-trials-in-early-alzheimers-disease Aduhelm should never have been approved for the treatment of Alzheimer's disease. The level of evidence required, is now based on the stage of disease. I think FDA is under pressure to make approvals. That could work in our favor. I don't think insurance companies would be a problem. There is a lack of options and Vascepa is not expensive. Sleven,
Market Data 
Markets 
AI
